ImmunityBio, Inc. (IBRX) financial statements and ratios from SEC XBRL: revenue $113.29M (TTM), net margin -310.2%, revenue growth 668.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $113.29M |
| Net Margin | -310.2% |
| Revenue Growth (YoY) | 668.3% |
| EPS Growth (YoY) | -35.6% |
| FCF Growth (YoY) | -22.4% |
| Price / Sales | 47.88 |
| FCF Yield | -6.6% |
| Altman Z-Score | -6.41 (distress) |
| Piotroski F-Score | 4/9 |
| Sector P/E (Healthcare) | 21.6 |
IBRX overview · IBRX earnings · IBRX KPIs · IBRX investor relations · IBRX ownership · IBRX peers · IBRX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.